Manhattan Scients
Manhattan Scientifics, Inc., a technology incubator, engages in the acquisition, development, and commercialization of life-enhancing technologies in the United States. It develops technologies in the areas of nano-technologies and nano-medicine. The company also offers nanostructured bulk metals and alloys in the form of rod, bar, wire, and foil for medical implants and other applications. The c… Read more
Manhattan Scients (MHTX) - Net Assets
Latest net assets as of June 2024: $-2.34 Million USD
Based on the latest financial reports, Manhattan Scients (MHTX) has net assets worth $-2.34 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($74.00K) and total liabilities ($2.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.34 Million |
| % of Total Assets | -3164.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 666.64 |
Manhattan Scients - Net Assets Trend (1999–2023)
This chart illustrates how Manhattan Scients's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Manhattan Scients (1999–2023)
The table below shows the annual net assets of Manhattan Scients from 1999 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-1.80 Million | -6.31% |
| 2022-12-31 | $-1.70 Million | -263.77% |
| 2021-12-31 | $1.03 Million | -77.86% |
| 2020-12-31 | $4.67 Million | +565.07% |
| 2019-12-31 | $-1.00 Million | -570.00% |
| 2018-12-31 | $-150.00K | -101.84% |
| 2017-12-31 | $8.16 Million | +199.71% |
| 2016-12-31 | $2.72 Million | -68.32% |
| 2015-12-31 | $8.59 Million | +1132.93% |
| 2014-12-31 | $-832.00K | +62.82% |
| 2013-12-31 | $-2.24 Million | -180.80% |
| 2012-12-31 | $-797.00K | -2254.05% |
| 2011-12-31 | $37.00K | -47.89% |
| 2010-12-31 | $71.00K | +108.37% |
| 2009-12-31 | $-848.00K | -0.71% |
| 2008-12-31 | $-842.00K | +21.53% |
| 2007-12-31 | $-1.07 Million | +54.99% |
| 2006-12-31 | $-2.38 Million | -43.44% |
| 2005-12-31 | $-1.66 Million | +7.46% |
| 2004-12-31 | $-1.80 Million | -54.96% |
| 2003-12-31 | $-1.16 Million | -83.10% |
| 2002-12-31 | $-633.00K | -141.87% |
| 2001-12-31 | $1.51 Million | -47.28% |
| 2000-12-31 | $2.87 Million | -10.99% |
| 1999-12-31 | $3.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Manhattan Scients's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4886800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $559.00K | % |
| Other Comprehensive Income | $-559.00K | % |
| Other Components | $70.61 Million | % |
| Total Equity | $-1.80 Million | 100.00% |
Manhattan Scients Competitors by Market Cap
The table below lists competitors of Manhattan Scients ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DongBang Medical
KQ:240550
|
$47.42K |
|
Cryomass Technologies Inc
OTCQX:CRYM
|
$47.43K |
|
Finnovate Acquisition Corp. Warrants
NASDAQ:FNVTW
|
$47.46K |
|
Bee Vectoring Technologies International Inc
PINK:BEVVF
|
$47.51K |
|
Shinhan WTI Futures ETN(H)
KO:500015
|
$47.39K |
|
NORDIC AMER TANKER
MU:B3O
|
$47.37K |
|
Sayward Capital Corp
V:SAWC-P
|
$47.35K |
|
COLOR STAR TECH. DL-001
F:2J4A
|
$47.32K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Manhattan Scients's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -1,695,000 to -1,802,000, a change of -107,000.
- Net loss of 1,165,000 reduced equity.
- Other comprehensive income increased equity by 499,000.
- Other factors increased equity by 559,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.17 Million | -64.65% |
| Other Comprehensive Income | $499.00K | +27.69% |
| Other Changes | $559.00K | +31.02% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Manhattan Scients's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $0.03 | $0.00 | x |
| 2000-12-31 | $0.03 | $0.00 | x |
| 2001-12-31 | $0.01 | $0.00 | x |
| 2002-12-31 | $-0.01 | $0.00 | x |
| 2003-12-31 | $-0.01 | $0.00 | x |
| 2004-12-31 | $-0.01 | $0.00 | x |
| 2005-12-31 | $-0.01 | $0.00 | x |
| 2006-12-31 | $-0.01 | $0.00 | x |
| 2007-12-31 | $0.00 | $0.00 | x |
| 2008-12-31 | $0.00 | $0.00 | x |
| 2009-12-31 | $0.00 | $0.00 | x |
| 2010-12-31 | $0.00 | $0.00 | x |
| 2011-12-31 | $0.00 | $0.00 | x |
| 2012-12-31 | $0.00 | $0.00 | x |
| 2013-12-31 | $0.00 | $0.00 | x |
| 2014-12-31 | $0.00 | $0.00 | x |
| 2015-12-31 | $0.01 | $0.00 | x |
| 2016-12-31 | $0.01 | $0.00 | x |
| 2017-12-31 | $0.02 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $0.00 | $0.00 | x |
| 2020-12-31 | $0.01 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
| 2023-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Manhattan Scients utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-300.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -304.16% | -980000.00% | 0.00x | 1.16x | $-10.12 Million |
| 2000 | -165.13% | -1894.40% | 0.07x | 1.28x | $-5.02 Million |
| 2001 | -440.61% | 0.00% | 0.00x | 1.92x | $-6.81 Million |
| 2002 | 0.00% | -2582.05% | 0.09x | 0.00x | $-3.96 Million |
| 2003 | 0.00% | -856.33% | 0.24x | 0.00x | $-2.45 Million |
| 2004 | 0.00% | -1011.33% | 0.12x | 0.00x | $-1.34 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-52.80K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.46 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.91 Million |
| 2008 | 0.00% | -250.23% | 0.84x | 0.00x | $-2.06 Million |
| 2009 | 0.00% | -70.46% | 0.71x | 0.00x | $-361.20K |
| 2010 | -60.56% | -2.55% | 0.87x | 27.14x | $-50.10K |
| 2011 | -6181.08% | -332.90% | 0.33x | 56.89x | $-2.29 Million |
| 2012 | 0.00% | -301.59% | 0.37x | 0.00x | $-2.01 Million |
| 2013 | 0.00% | -295.71% | 0.35x | 0.00x | $-1.70 Million |
| 2014 | 0.00% | -592.68% | 0.18x | 0.00x | $-3.72 Million |
| 2015 | 93.23% | 12518.75% | 0.00x | 1.50x | $7.15 Million |
| 2016 | -224.31% | -4072.00% | 0.02x | 2.80x | $-6.38 Million |
| 2017 | 18.94% | 1088.73% | 0.01x | 1.33x | $729.90K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.32 Million |
| 2019 | 0.00% | -1259.79% | 0.04x | 0.00x | $-1.12 Million |
| 2020 | 92.30% | 8628.00% | 0.01x | 1.47x | $3.85 Million |
| 2021 | -351.59% | -7278.00% | 0.01x | 3.34x | $-3.74 Million |
| 2022 | 0.00% | -5460.00% | 0.05x | 0.00x | $-2.56 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-984.80K |
Industry Comparison
This section compares Manhattan Scients's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Manhattan Scients (MHTX) | $-2.34 Million | -304.16% | N/A | $47.42K |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |